I am thrilled to share that today Kimia announced the closing of our $55 Million Series A raise. This will enable us to expand the ATLAS platform and develop a broad range of therapeutic targets in oncology, immunology and inflammation. As the leader of the technology group I am excited about integrating a validated drug discovery platform with state-of-the-art computational tools to accelerate the discovery of novel drugs and bring better therapies to patients faster. To learn more please visit our website: www.kimiatx.com
I’m delighted to congratulate the entire Kimia team on the close of the $55M Series A that was announced today. Over the past several months, the Kimia team has done a phenomenal job getting the company off the ground. Also a big thanks to our supportive investors. I very much look forward to working with all of you and to sharing the journey ahead of us. Together, we will build out the ATLAS platform and create a chemical map of the druggable proteome, identify novel sites for therapeutic intervention, and accelerate the discovery of new and better medicines. To learn more please visit our new website: www.kimiatx.com Stig